Institute of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheung Kung University, Tainan, Taiwan.
J Neurotrauma. 2012 May 1;29(7):1518-29. doi: 10.1089/neu.2011.2030. Epub 2012 Mar 29.
Magnesium sulfate and nimesulide are commonly used drugs with reported neuroprotective effects. Their combination as stroke treatment has the potential benefits of decreasing individual drug dosage and fewer adverse effects. This study evaluated their synergistic effects and compared a low-dose combination with individual drug alone and placebo. Sprague-Dawley rats underwent 90 min of focal ischemia with intraluminal suture occlusion of the middle cerebral artery followed by reperfusion. The rats were randomly assigned to receive one of the following treatments: placebo, magnesium sulfate (MgSO₄; 45 mg/kg) intravenously immediately after the induction of middle cerebral artery occlusion, nimesulide (6 mg/kg) intraperitoneally before reperfusion, and combined therapy. Three days after the ischemia-reperfusion insult, therapeutic outcome was assessed by 2,3,5-triphenyltetrazolium chloride staining and a 28-point neurological severity scoring system. Cyclooxygenase-2, prostaglandin E₂, myeloperoxidase, and caspase-3 expression after treatment were evaluated using Western blot analyses and immunohistochemical staining, followed by immunoreactive cell analysis using tissue cytometry. Only the combination treatment group showed a significant decrease in infarction volume (10.93±6.54% versus 26.43±7.08%, p<0.01), and neurological severity score (p<0.05). Low-dose MgSO₄ or nimesulide showed no significant neuroprotection. There was also significant suppression of cyclooxygenase-2, prostaglandin E₂, myeloperoxidase, and caspase-3 expression in the combination treatment group, suggesting that the combination of the two drugs improved the neuroprotective effects of each individual drug. MgSO₄ and nimesulide have synergistic effects on ischemia-reperfusion insults. Their combination helps decrease drug dosage and adverse effects. Combined treatment strategies may help to combat stroke-induced brain damage in the future.
硫酸镁和尼美舒利是常用的具有神经保护作用的药物。它们联合用于治疗中风可以减少单个药物剂量并减少不良反应。本研究评估了它们的协同作用,并比较了低剂量联合用药与单独用药和安慰剂的效果。Sprague-Dawley 大鼠接受 90 分钟的大脑中动脉结扎局灶性缺血,然后再进行再灌注。大鼠随机接受以下治疗之一:安慰剂、缺血后立即静脉注射硫酸镁(45mg/kg)、再灌注前腹腔内注射尼美舒利(6mg/kg)和联合治疗。缺血再灌注损伤后 3 天,通过 2,3,5-三苯基氯化四氮唑染色和 28 分神经严重程度评分系统评估治疗效果。用 Western blot 分析和免疫组化染色评估治疗后环氧化酶-2、前列腺素 E₂、髓过氧化物酶和半胱氨酸天冬氨酸蛋白酶-3 的表达,并通过组织细胞计数进行免疫反应性细胞分析。只有联合治疗组梗死体积(10.93±6.54%对 26.43±7.08%,p<0.01)和神经严重程度评分(p<0.05)明显降低。低剂量硫酸镁或尼美舒利无明显神经保护作用。联合治疗组还明显抑制环氧化酶-2、前列腺素 E₂、髓过氧化物酶和半胱氨酸天冬氨酸蛋白酶-3 的表达,表明两种药物联合使用提高了每种药物的神经保护作用。硫酸镁和尼美舒利对缺血再灌注损伤具有协同作用。它们的联合使用有助于减少药物剂量和不良反应。联合治疗策略可能有助于将来对抗中风引起的脑损伤。